Determination of the Optimal Volume of 0.5% Bupivacaine Liposome in Single-Injection Interscalene Brachial Plexus Block: A Bayesian Phase I/II Trial
Condition(s) studied
Investigational drug(s) / intervention(s)
Bupivacaine Liposomes(BL): Prior to surgery, an interscalene brachial plexus block was performed, injecting the preset volume of 0.5% bupivacaine liposomes according to the Bayesian optimal interval method.
Study summary
This single-center, prospective, single-arm, Bayesian phase I/II clinical trial evaluates the incidence of HDP following ISB in shoulder arthroscopy and determines the optimal volume of a single injection of liposomal bupivacaine.
Eligibility
Primary outcome measure(s)
- Hemidiaphragmatic paresis incidence rate(Phase Ⅰ) — Perioperative
The diaphragmatic excursion was measured using ultrasound 0.5 hours after the completion of the nerve block, and partial or complete unilateral Hemidiaphragmatic paresis(HDP) was assessed based on the diaphragmatic excursion. No excursion was defined as ≤25%, partial excursion as \>25% and ≤75%, and complete excursion as \>75%. A diaphragmatic excursion greater than or equal to 25% measured by ultrasound can be defined as HDP. - Success rate of interscalene brachial plexus block (Phase II) — Perioperative
Before the surgery, an ultrasound-guided interscalene brachial plexus block is performed. After the surgery, when the patient is fully awake, a simplified sensory-motor assessment scale is used for evaluation. A comprehensive score of ≥12 is defined as a successful nerve block.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Jiaxing University Affiliated Hospital | Jiaxing | Zhejiang |
More Affiliated Hospital of Jiaxing University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06972680 on ClinicalTrials.gov ↗ ← All trials in China